Merit Medical Systems Inc

JNJ’s Interventional Solutions segment generated third-quarter net revenues of $653.0 million, compared to $553.0 million in the third quarter of 2017.

Of the 22 analysts covering Edwards Lifesciences in February 2018, 17 analysts have given the stock a “buy” or a higher rating.

In December 2017, Edwards Lifesciences (EW) acquired Harpoon Medical for a total consideration of $119.5 million.

In 3Q17, Merit Medical Systems’ cardiovascular segment generated revenues of $172.7 million—compared to $150.5 million in 3Q16.

Of the eight analysts covering Merit Medical Systems in February, four gave it a “strong buy,” three gave it a “buy,” and one gave it a “sell” rating.